Table 1 GO and KEGG pathway enrichment analysis of DEGs in the high-ESR1 group
| Â | Category | Term | Count | p value | Genes (partial) |
|---|---|---|---|---|---|
Upgrade | BP | Signal transduction | 69 | 1.3E−04 | DLC1, GNA14, CLDN3, WISP2, CDKL2, TNFRSF10C, CCR6, C3, KIT, GPRC5A, CCL20, CD4, ITK |
BP | Immune response | 60 | 7.8E−19 | CHIA, SUSD2, HLA-DMA, CXCR5, SPN, NCR3, TNFRSF10C, CCR2, C3, CXCL2, CCL20, CD4 | |
BP | Cell adhesion | 49 | 1.1E−10 | CXCR3, WISP2, ICAM1, NCAM2, ITGAL, VCAM1, COMP, CD2, THBS4, DPT, TNXB, CASS4 | |
CC | Integral component of membrane | 262 | 2.5E−10 | CCR5, ROR1, MST1R, CYP1B1, ICM1, MMP13, CD22, ABCA3, MUC1, VCAM1 | |
CC | Plasma membrane | 255 | 5.7E−21 | CADM3, AQP1, BTK, ADAM8, ROS1, PIK3CG, CDHR4, CCR5, RAB17, KDR, ICAM1, C3, CD4, MRC1 | |
CC | Extracellular exosome | 182 | 9.3E−16 | PDGFD, MUC1, BMP3, WISP2, ICAM1, AGT, FGG, C3, CD4, CPM | |
MF | Calcium ion binding | 41 | 4.1E−03 | MMP28, FAT4, COMP, ADAM8, CAPN9, CDHR4, PCDHAC1 | |
MF | Protein homodimerization activity | 37 | 3.6E−02 | CADM3, PTGS2, KIT, CD2, CEACAM5, MUC13, FLT3, S100B, CCR2, AOC3 | |
MF | Receptor binding | 30 | 3.4E−05 | CADM3, C3, BLK, BTK, PGR, FGA, RSRO3, TNFSF8, CCL13 | |
KEGG | Cell adhesion molecules (CAMs) | 33 | 9.8E−15 | ITGAL, CADM3, CLDN9, ITGB2, HLA-DMA, ITGAM, VCAM1, CD2, SELPLG, SPN, ICAM1, PTPRC | |
KEGG | Cytokine-cytokine receptor interaction | 29 | 3.1E−06 | GDF5, CXCL2, IL21R, CXCR5, LTB, CSF1R, TNFRSF17, TNFSF8, CCR7, CCL13, CCR6, CD40LG | |
KEGG | Hematopoietic cell lineage | 28 | 2.1E−16 | HLA-DRB1, FCER2, KIT, ITGB3, ITGAM, MS4A1, CD4, CSF3R, CR1, FLT3, CD1A | |
Downgrade | BP | Positive regulation of transcription from RNA polymerase II promoter | 37 | 1.9E−03 | FGFR2, WNT3A, E2F7, SOX2, TP63, JAG1, BARX1, NRG1, DMRT1, CHP2, SIX2, GAL, HMGA2, ITGA6, BMP7 |
BP | Negative regulation of transcription from RNA polymerase II promoter | 26 | 1.7E−02 | FGFR2, E2F7, SOX2, MAGEA1, TP63, NRARP, TRIM29, DMRT1, VAX1, HMGA2, NR0B1, DLX1, FOXE1, TBX18 | |
BP | Oxidation–reduction process | 25 | 3.1E−03 | CYP26A1, OSGIN1, ADH7, ALDH3A1, SESN3, FMO6P, CYP4F3, NOS2, AKR1C1 | |
CC | Extracellular exosome | 84 | 2.6E−03 | WNT3A, RASSF9, SERPINB5, PI3, CNTN1, RAB3B, UGT1A6, KRT5, TGM1, LGALS7, DSC1, IGFBP2, PSAT1 | |
CC | Extracellular region | 55 | 1.2E−03 | WNT3A, JAG1, NRCAM, NRG1, CLCA2, TMPRSS11A, FGFR2, ADH7, FBN2, WNT2B, SOST, BMP7, IGFBP2 | |
CC | Extracellular space | 52 | 9.9E−05 | WNT3A, FGF12, NRG1, MMP10, SERPINB5, FGFBP1, LGALS7, KRT31, WNT2B, SOST, IGFL1, BMP7, IGFBP2 | |
MF | Structural molecule activity | 32 | 7.7E−15 | JAG1, KRT5, CLDN20, SPRR1A, KRT16, SPRR3, CSTA, ADD2 | |
MF | Calcium ion binding | 31 | 8.6E−04 | NELL1, JAG1, NECAB2, CDH8, ANXA8, RPTN, FAT2, TGM3, FBN2, S100A2, CDHR1, CABYR, MMP10, DSC1 | |
MF | Transcription factor activity, sequence-specific DNA binding | 31 | 4.4E−02 | E2F7, SOX2, TP63, ZIC1, BARX1, HOXC8, FOXD1, PITX1, TRIM29, SIX2, DLX2, FOXE1, TBX18, TCF15 | |
KEGG | Metabolism of xenobiotics by cytochrome P450 | 15 | 2.8E−10 | GSTA1, CYP2S1, ADH7, UGT1A1, ALDH3A1, GSTM3, UGT1A8, UGT1A3, UGT2A1, AKR1C1 | |
KEGG | Neuroactive ligand-receptor interaction | 14 | 5.5E−03 | GABRR1, PTH2R, CHRM3, P2RY1, S1PR5, LPAR3, GPR50, CHRNB2, ADRA2B, HTR2C, GABRQ | |
KEGG | Drug metabolism—cytochrome P450 | 12 | 1.4E−07 | GSTA1, UGT1A7, UGT1A10, GSTM3, UGT1A9, UGT2A1, ADH7, UGT1A1, ALDH3A1 |